Thymagen (Thymogen): A Khavinson-Family Dipeptide Bioregulator Studied in Immune-Function Models

Research summary. Thymagen, also marketed in Russia under the name Thymogen, is the dipeptide Glu-Trp (EW), the smallest member of the Khavinson "peptide bioregulator" family. It was originally isolated as an active fragment of larger thymic-extract preparations and is now produced synthetically. The published Russian literature reports immunomodulatory effects centred on T-cell function, interferon secretion, and host defence against viral and bacterial pathogens. Thymagen is approved as a prescription immunomodulator in Russia and several CIS countries, though it is not approved by the FDA or EMA. Mechanistic claims regarding direct gene-expression effects in thymic and immune tissues follow the broader Khavinson bioregulator pattern.

Molecular profile

• Sequence: Glu-Trp (EW)
• Class: Khavinson-family dipeptide; immunomodulatory bioregulator
• Synonyms: Thymogen; Glutamyl-tryptophan; γ-Glu-Trp (some preparations)
• Approval status: Approved as a prescription immunomodulator in Russia; not FDA- or EMA-approved
• Origin: Originally derived from calf-thymus extracts, now produced synthetically

Mechanism of action

Thymagen is reported to act through immunomodulatory pathways involving thymic-tissue effects and downstream T-cell function:

• T-cell maturation and function. Reported effects on thymic-tissue gene expression and on T-cell maturation in immune-deficient or thymus-compromised models.
• Interferon secretion. Reported increases in interferon production by immune cells following Thymagen administration, supporting reported antiviral activity.
• Cyclic-nucleotide signalling. The Russian research literature describes Thymagen as modulating intracellular cAMP and cGMP signalling in immune cells, providing a proposed second-messenger mechanism.
• Heterochromatin and gene-expression effects. Consistent with the broader Khavinson bioregulator framework; reported effects include decondensation of heterochromatin in lymphocytes and changes in expression of immune-relevant genes.

The mechanistic picture in the originating literature is of a "thymus-resetting" peptide that supports normal immune function rather than producing supraphysiological immune stimulation.

Preclinical and clinical research highlights

Hepatitis B and C. Russian clinical research has reported that Thymagen administration as adjunctive therapy is associated with improved viral-clearance and clinical-recovery endpoints in hepatitis-B and hepatitis-C infection.

Post-operative infection and recovery. Reported applications include reduction of post-operative infectious complications and improvement of immune-recovery endpoints in surgical-patient populations.

Cancer-adjuvant research. Russian research has explored Thymagen as an immune-supportive adjunct in oncology populations, with reported modulation of innate-immune endpoints.

Cardiovascular and metabolic-disease applications. Some published work has reported effects in cardiovascular disease and diabetes contexts, attributed to the broader systemic effects of immune-system modulation.

Influenza and respiratory infection. Reported effects on antiviral immunity have been investigated in respiratory infection contexts.

Limitations of the evidence base

• The published Thymagen / Thymogen literature is concentrated almost entirely in Russian research groups, with limited independent Western replication.
• Western regulatory approval is absent; clinical evidence does not currently meet FDA or EMA standards for any infectious-disease or oncology indication.
• The very small (dipeptide) size of Thymagen places mechanistic claims in the same conceptual category as other Khavinson bioregulators, where direct-DNA-interaction claims remain debated outside the originating programme.

Current research status

Thymagen / Thymogen is not approved by the FDA or EMA. It is approved as a prescription immunomodulator in Russia. Research-grade Thymagen is supplied for laboratory use only.

For research-supplier contexts, Thymagen is supplied as a research-grade investigational peptide and is not intended for self-administration.

Key takeaways for researchers

• Thymagen / Thymogen is the dipeptide Glu-Trp, the smallest member of the Khavinson bioregulator family.
• Reported mechanisms include T-cell maturation support, interferon secretion induction, cyclic-nucleotide signalling modulation, and gene-expression effects in immune tissues.
• Reported clinical applications in Russian literature include hepatitis B/C, post-operative recovery, cancer-adjuvant research, and respiratory infection.
• Thymagen is approved in Russia but is not FDA- or EMA-approved.
• The published literature is concentrated in the originating Russian research programme; independent Western replication is limited.

References

1. Khavinson VK, Solovyev AY, Tarnovskaya SI, Lin'kova NS. Mechanism of biological activity of short peptides: cell penetration and epigenetic regulation of gene expression. Bull Exp Biol Med. 2014;156(5):635–639.
2. Anisimov VN, Khavinson VK. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139–149.

---

This article is provided for educational and research purposes only. Thymagen / Thymogen is a research peptide. It is not an approved drug or therapeutic agent in the United States or European Union and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. All work involving this peptide should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.